China’s Sunpower To Acquire Valeant’s US Biopharma Unit Dendreon For $819M

Login to View

Chinese companies remain active buyers of overseas healthcare related assets.  Privately owned conglomerate Sanpower Group has agreed to acquire Valeant’s biopharma unit Dendreon for US$819.9 million, as Valeant aims to offload its non-core assets, the companies announced.

Continue reading with a China Money Network subscription


Join Now

Already have an account or paid subscription? Log in


RELATED NEWS



LEAVE A REPLY

Please enter your comment!
Please enter your name here